doi:10.1111/j.1523-1755.2004.00790.x 25
In a 14-week extension study of Liraglutide Effect and Action in Diabetes 6 trial, patients switched from 10 g twice-daily exenatide to 1.8 mg liraglutide once-daily or 40 weeks of continued liraglutide
Post hoc analysis of some of the large cardiovascular outcome trials of GLP-1 receptor agonists confirmed the renal protective effects: The LEADER trial , 25 in further analysis, showed a relative risk reduction in nephropathic events of 22% (NNT 25) in the liraglutide group compared with placebo
20 , se tenan en cuenta otras variables clnicas, como la ganancia ponderal o la apnea
Consistency in dosing and dietary habits will enhance the drugs effectiveness
Study findings revealed that, while absolute muscle mass decreased slightly, the muscle-to-body-weight ratio improved in mice, and the lean-body-mass-to-body-weight ratio improved